Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAGNODE-B booster intralymphatic Diamyd study in type 1 diabetes
2021-005441-32Phase 2Completed
- Sponsor
- Linköping University
- Start
- Oct 2021
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Diamyd in diabetes mellitus type 1 (T1D), sponsored by Linköping University. Primary endpoint: Feasibility and safety of additional booster dose. Started Oct 2021; status: completed.
02
Drugs
Diamyd
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2021-005441-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005441-32.